Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tuoduqingying (also known as Tuoduqingying suppository or Detoxifying Qingying suppository) is a novel vaginal traditional Chinese medicine (TCM) suppository developed by Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine. It is indicated for the treatment of persistent high-risk cervical human papillomavirus (HPV) infection. The suppository is designed to facilitate HPV clearance, reduce recurrence rates, and improve the vaginal microenvironment and local immune response. It has been evaluated in clinical trials in China against standard treatments like recombinant human interferon alpha-2b.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Tuoduqingying.